ReviewClinical and experimental gastroenterology2014
Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review.
Review in Clinical and experimental gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- External therapy of traditional Chinese medicine for treating irritable bowel syndrome with diarrhea: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Acupuncture for Adults with Diarrhea-Predominant Irritable Bowel Syndrome or Functional Diarrhea: A Systematic Review and Meta-Analysis.Neural plasticity · 2020Pooled it
- Ameliorating effects and mechanisms of transcutaneous auricular vagal nerve stimulation on abdominal pain and constipation.JCI insight · 2021Trial
- Otilonium bromide exhibits novel antifungal activity againstVirulence · 2026Article
- Comparative Effectiveness of Mebeverine and Otilonium Bromide on Health-Related Quality of Life in Patients with Irritable Bowel Syndrome: A Prospective Cohort Study.Life (Basel, Switzerland) · 2026Article
- [Treatment of Irritable Bowel Syndrome with Predominant Diarrhea].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Review
- Otilonium Bromide Prevents Cholinergic Changes in the Distal Colon Induced by Chronic Water Avoidance Stress, a Rat Model of Irritable Bowel Syndrome.International journal of molecular sciences · 2023Article
- Otilonium bromide boosts antimicrobial activities of colistin against Gram-negative pathogens and their persisters.Communications biology · 2022Article
- Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity.Antimicrobial agents and chemotherapy · 2021Article
- Article
- Otilonium Bromide treatment prevents nitrergic functional and morphological changes caused by chronic stress in the distal colon of a rat IBS model.Journal of cellular and molecular medicine · 2021Article
- Irritable Bowel Syndrome: News from an Old Disorder.GE Portuguese journal of gastroenterology · 2020Review
- Repurposing Antispasmodic Agent Otilonium Bromide for Treatment ofFrontiers in microbiology · 2020Article
- Article
- Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis.Therapeutic advances in gastroenterology · 2017Article
- Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.Neurogastroenterology and motility · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a very common functional gastrointestinal disorder characterized by abdominal pain or discomfort and altered bowel habits. The disease affects a large part of the world population. The clinical course is mostly characterized by a cyclic recurrence of symptoms. Therefore, IBS patients should receive, as an initial therapeutic approach, a short course of treatment, and long-term treatment should be reserved for those patients with recurrent symptoms. The available clinical trials show that significant improvement of the symptoms over placebo could be achieved with various drugs, although this improvement is frequently time dependent and with high relapse rates after the cessation of the treatment. In a proportion of patients, clinically obvious relapse could appear long after stopping the treatment. Some of the available pharmacologic agents, including otilonium bromide (OB), are able to significantly prolong the time to the appearance of relapse, compared with placebo. As a consequence, some authors suggest that a cyclic treatment could be of benefit. Antispasmodic drugs have been used for many years in an effort to control the symptoms of IBS. OB is a poorly absorbed spasmolytic drug, exerting significantly greater control of the symptoms of IBS compared with placebo. Recent data suggest that the drug could effectively be used for the long-term management of patients with IBS. The aim of this review is to provide the reader with an evidence-based overview of the efficacy and tolerability of OB in the long-term management of IBS patients, based on the results of the clinical trials published so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.